BioinvestGPT ApS · Research use only
BVCT ex-ante predictions by clinical trial
BVCT made 692 dated, ex-ante predictions for 690 clinical trials registered on ClinicalTrials.gov, covering 704 readouts: 699 scored and 5 not adjudicable. Each trial below links to a page with the prediction date, the recorded calls, the readout and its dashboard classification.
6 further records use other registries or no registry ID and appear on the dashboard only.
- Neoplasms (192)
- Nervous System Diseases (117)
- Immune System Diseases (80)
- Nutritional and Metabolic Diseases (60)
- Respiratory Tract Diseases (41)
- Cardiovascular Diseases (31)
- Skin and Connective Tissue Diseases (31)
- Mental Disorders (25)
- Musculoskeletal Diseases (23)
- Eye Diseases (21)
- Infections (20)
- Hemic and Lymphatic Diseases (12)
- Cardiovascular Diseases and Nutritional and Metabolic Diseases (10)
- Urogenital Diseases (8)
- Endocrine System Diseases (6)
- Digestive System Diseases (4)
- Hematologic Diseases (4)
- Congenital; Hereditary; and Neonatal Diseases and Abnormalities (1)
- Nervous System Diseases / Genetic Diseases (1)
- Nutritional and Metabolic Diseases and Urogenital Diseases (1)
- Nutritional and Metabolic Diseases, Immune System Diseases (1)
- Renal Replacement Therapy (1)
Neoplasms (192)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT01436968PrTK03 | CAN2409 | localized prostate cancer | Phase 3 | Correct PredictionTN |
| NCT02768363ULYSSES | CAN2409 | newly diagnosed prostate cancer | Phase 2 | Correct PredictionTN |
| NCT02831959METIS | NovoTTF-200M device Best Standard of Care | Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
| NCT02947685PATINA | Palbociclib | HR+/HER2+ advanced breast cancer | Phase 3 | Correct PredictionTP |
| NCT03377491PANOVA-3 | NovoTTF-200T | Pancreatic Cancer | Phase 3 | Correct PredictionTP |
| NCT03504488 | CAB-ROR2-ADC PD-1 inhibitor | TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT03526835 | Petosemtamab (MCLA-158) | 1L/2L/3L metastatic colorectal cancer (mCRC) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT03602859FIRST | Dostarlimab (TSR-042) | 1L combotherapy treatment for advanced ovarian cancer | Phase 3 | Correct PredictionTN |
| NCT03616470 | Uproleselan (GMI-1271) | Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Correct PredictionTN |
| NCT03674567 | FLX475 Pembrolizumab | Advanced Cancer | Phase 1 Phase 2 | Correct PredictionTN |
| NCT03686124ACTengine | IMA203 | Recurrent and/or Refractory Solid Tumors | Phase 1 | Correct PredictionTP |
| NCT03698552 | ADCT-602 | Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT03715933 | INBRX-109 | 3L+ mCRC | Phase 1 | Correct PredictionTP |
| NCT03816163GLEAM | Zolbetuximab (IMAB362) | 1L metastatic pancreatic adenocarcinoma (PDAC) | Phase 2 | Correct PredictionTN |
| NCT03881488 | CTX-471 pembrolizumab | Metastatic or Locally Advanced Malignancies | Phase 1 | Correct PredictionTP |
| NCT03922204 | MCLA-145 | Advanced or Metastatic Malignancies | Phase 1 | Correct PredictionTP |
| NCT03937219COSMIC-313 | Cabozantinib | Renal Cell Carcinoma | Phase 3 | Correct PredictionTN |
| NCT03941093LAPIS | Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX | Locally Advanced Pancreatic Cancer | Phase 3 | Correct PredictionTN |
| NCT03967223IGNYTE-ESO | Letetresgene autoleucel (lete-cel; GSK3377794) | advanced synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS) | Phase 2 | Correct PredictionTP |
| NCT04065399AUGMENT-101 | Revumenib (SNDX-5613) | mNPM1-mutant relapsed/refractory Leukemias | Phase 2 | Correct PredictionTN |
| NCT04067336KOMET-001 | Ziftomenib | Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04104672ARC-8 | AB680 Zimberelimab Nab-paclitaxel Gemcitabine | Advanced Pancreatic Cancer | Phase 1 | Correct PredictionTN |
| NCT04158336 | ZN-c3 | Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT04246047DREAMM 7 | belantamab mafodotin | Relapsed/Refractory Multiple Myeloma | Phase 3 | Correct PredictionTN |
| NCT04294810SKYSCRAPER-01 | Tiragolumab | Non-Small Cell Lung Cancer | Phase 3 | Correct PredictionTN |
| NCT04363801DisTinGuish | Sirexatamab (DKN-01) | Gastric or Gastroesophageal Cancer | Phase 2 | Correct PredictionTN |
| NCT04387461CORE-001 | CG0070 Pembrolizumab Injection n-dodecyl-B-D-maltoside | Non-Muscle Invasive Bladder Cancer | Phase 2 | Correct PredictionTP |
| NCT04389632 | sigvotatug vedotin (SGN-B6A) pembrolizumab cisplatin carboplatin | Carcinoma Non-Small Cell Lung Squamous Cell Carcinoma of Head and Neck HER2 Negative Breast Neoplasms Esophageal Squamous Cell Carcinoma Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Neoplasms Cutaneous Squamous Cell Cancer Exocrine Pancreatic Adenocarcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms Stomach Neoplasms | Phase 1 | Correct PredictionTP |
| NCT04401748Verona | Venetoclax | 1L higher-risk myelodysplastic syndrome (HR-MDS) | Phase 3 | Missed PredictionFP |
| NCT04429542 | Ficerafusp Alfa (BCA101) | EGFR-driven Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT04452591BOND-003 | CG0070 n-dodecyl-B-D-maltoside | Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin | Phase 3 | Correct PredictionTN |
| NCT04459715TrilynX | Xevinapant (Debio 1143) Cisplatin Intensity Modulation Radiation Therapy (IMRT) Placebo | Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Correct PredictionTN |
| NCT04484623DREAMM 8 | belantamab mafodotin | Relapsed/Refractory Multiple Myeloma | Phase 3 | Correct PredictionTN |
| NCT04487080MARIPOSA | Amivantamab | EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
| NCT04493853CAPItello-281 | Capivasertib | Hormone-Sensitive Prostate Cancer | Phase 3 | Correct PredictionTP |
| NCT04494425DB-06 | Trastuzumab deruxtecan Capecitabine Paclitaxel Nab-Paclitaxel | Metastatic Breast Cancer | Phase 3 | Correct PredictionTP |
| NCT04495153 | Aglatimagene besadenovec (CAN-2409) | Stage III/IV NSCLC | Phase 2 | Correct PredictionTN |
| NCT04503278 | BTN211-01 | Advanced solid tumors | Phase 1 | Correct PredictionTN |
| NCT04513925SKYSCRAPER-03 | Tiragolumab | Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
| NCT04527991TROPiCS-04 | Sacituzumab Govitecan-hziy Paclitaxel Docetaxel Vinflunine | Metastatic or Locally Advanced Unresectable Urothelial Cancer | Phase 3 | Missed PredictionFP |
| NCT04534205AHEAD-MERIT | BNT113 | Head and Neck Cancer | Phase 2 | Correct PredictionTN |
| NCT04561362Duravelo-1 | BT8009 | metastatic urothelial cancer | Phase 1 Phase 2 | Correct PredictionTP |
| NCT04585750PYNNACLE | Rezatapopt (PC14586) | advanced Solid Tumors Harboring a TP53 Y220C Mutation | Phase 1 Phase 2 | Correct PredictionTP |
| NCT04606446KAT6 | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer Locally Advanced or Metastatic Castration-resistant Prostate Cancer Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 | Correct PredictionTN |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab | Melanoma Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Correct PredictionTN |
| NCT04660812ARC-9 | AB680 Etrumadenant Zimberelimab Bevacizumab m-FOLFOX-6 regimen Regorafenib | Metastatic Colorectal Cancer | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04660929 | CT-0508 Pembrolizumab | HER2-positive Adenocarcinoma Bile Duct Cancer Biliary Tract Cancer Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma Ductal Carcinoma Hepatocellular Cancer Lung Cancer Non-Small Cell Carcinoma Ovarian Epithelial Carcinoma Small Cell Carcinoma Squamous Carcinoma Transitional Cell Colorectal Cancer Esophagogastric Junction Neoplasms Inflammatory Breast Cancer Stomach Neoplasms Malignant Neoplasms Ovarian Neoplasms Pancreatic Cancer HER2- positive Solid Tumors HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression HER-2 Gene Amplification Prostate Cancer Head and Neck Cancer Endometrial Cancer Lung Cancer Small Cel | Phase 1 | Correct PredictionTN |
| NCT04675294ASPEN-03 | Evorpacept (ALX148) | Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Correct PredictionTN |
| NCT04675333ASPEN-04 | Evorpacept (ALX148) | Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Correct PredictionTN |
| NCT04680052InMIND | Tafasitamab Rituximab Lenalidomide Placebo | Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma | Phase 3 | Correct PredictionTP |
| NCT04720157PSMAddition | 177Lu-PSMA-617 | 1L PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) | Phase 3 | Correct PredictionTN |
| NCT04797780SELECT MDS-1 | Tamibarotene | Myelodysplastic Syndrome with RARA gene overexpression | Phase 3 | Correct PredictionTN |
| NCT04799249PRESERVE 2 | Trilaciclib Placebo Gemcitabine Carboplatin | TNBC - Triple-Negative Breast Cancer | Phase 3 | Missed PredictionFP |
| NCT04811027TACTI-003 | Eftilagimod alpha | Recurrent or Metastatic HNSCC | Phase 2 | Correct PredictionTP |
| NCT04814108TETON | ZN-c3 | Uterine Serous Carcinoma | Phase 2 | Correct PredictionTN |
| NCT04824794 | HexaBody-CD38 (GEN3014) | relapsed or refractory multiple myeloma (RRMM) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT04849910 | VOR33 | CD33+ acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04855656MYTHIC | lunresertib (RP-6306) and camonsertib (RP-3500) | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT04905407SELECT-AML-1 | Tamibarotene Venetoclax Azacitidine | Acute Myeloid Leukemia | Phase 2 | Correct PredictionTN |
| NCT04975308EMBER-3 | Imlunestrant | 2L HR+/HER2- Metastatic Breast Cancer | Phase 3 | Correct PredictionTP |
| NCT04975997EXCALIBER-RRMM | iberdomide | Relapsed or Refractory Multiple Myeloma | Phase 3 | Correct PredictionTP |
| NCT04996875APEX | bezuclastinib | Advanced Systemic Mastocytosis (AdvSM) | Phase 2 | Correct PredictionTP |
| NCT04999969 | AZD0171 | 1L treatment for advanced pancreatic ductal adenocarcinoma (PDAC) | Phase 2 | Missed PredictionFP |
| NCT05002127ASPEN-06 | Evorpacept (ALX148) | Advanced HER2+ Gastric Cancer | Phase 2 Phase 3 | Correct PredictionTP |
| NCT05002569RELATIVITY-098 | Relatlimab | post-resection stage III-IV melanoma | Phase 3 | Correct PredictionTN |
| NCT05020678 | NKX019 | relapsed/refractory B cell malignancies | Phase 1 | Correct PredictionTN |
| NCT05023980BRUIN CLL-313 | Pirtobrutinib (LOXO-305) | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Correct PredictionTP |
| NCT05029882 | ABBV-400 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05039177HERKULES-3 | ERAS-007 Encorafenib Cetuximab Palbociclib | Advanced Gastrointestinal Malignancies | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05047536 | KZR-261 | Advanced Solid Malignancies | Phase 1 | Correct PredictionTN |
| NCT05059262MOTION | Vimseltinib (DCC-3014) | Tenosynovial Giant Cell Tumor (TGCT) | Phase 3 | Correct PredictionTP |
| NCT05067140 | ARV-766 Part A&B ARV-766 + Abiraterone Part C&D | Metastatic Prostate Cancer | Phase 1 | Correct PredictionTP |
| NCT05074810RAMP203 | Avutometinib (VS-6766) | 1L or 2L KRAS-G12C-mutant NSCLC patients | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05081609IL Believe | TransCon IL-2 β/γ Pembrolizumab Chemotherapy drug TransCon TLR7/8 Agonist Surgery | Solid Tumor Malignancies | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05089734EVOKE-01 | Sacituzumab Govitecan-hziy (SG) Docetaxel | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
| NCT05109442 | AFM24 | Selected Advanced/Metastatic EGFR-expressing Cancers | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05111626FORTITUDE-102 | Bemarituzumab | 1L advanced gastric cancer/ GEJ cancer with FGFR2b over expression | Phase 3 | Missed PredictionFP |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy | Triple Negative Breast Cancer | Phase 2 | Correct PredictionTP |
| NCT05118789ARROS-1 | Zidesamtinib (NVL-520) | Advanced NSCLC and Other Solid Tumors | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05128825DENALI | ZN-c3 | High-Grade Serous Ovarian; Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Correct PredictionTN |
| NCT05130866POPLAR-NF2 | REC-2282 | Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05131022 | NX-5948 | Relapsed/Refractory B-cell Malignancies | Phase 1 | Correct PredictionTN |
| NCT05141721GRANITE | GRT-C901 GRT-R902 Atezolizumab Ipilimumab Fluoropyrimidine plus leucovorin Bevacizumab | Metastatic Colorectal Cancer | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05147350MINOTAUR | RP-6306 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05152147HERIZON-GEA-01 | Zanidatamab | 1L HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Phase 3 | Correct PredictionTP |
| NCT05163041 | BT7480 | Advanced Solid Tumor | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05186753SUMMIT | Bezuclastinib | Indolent or Smoldering Systemic Mastocytosis | Phase 2 | Correct PredictionTP |
| NCT05188729 | LTX-315 Part 1 VP-315 Part 2 | Basal Cell Carcinoma | Phase 2 | Correct PredictionTN |
| NCT05191667 | AN0025 and Chemoradiotherapy | Esophageal Cancer | Phase 1 | Correct PredictionTN |
| NCT05198804 | ZN-c3 (azenosertib) | 2L advanced ovarian cancer | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05208047PEAK | Bezuclastinib | Gastrointestinal Stromal Tumors (GIST | Phase 3 | Correct PredictionTP |
| NCT05208944THIO-101 | Cemiplimab | 3L advanced NSCLC | Phase 2 | Correct PredictionTP |
| NCT05210790VERIFY | Rusfertide | Polycythemia Vera (PV) | Phase 3 | Correct PredictionTP |
| NCT05216432ReDiscover | RLY-2608 | Advanced Breast Cancer | Phase 1 | Correct PredictionTP |
| NCT05219500TATCIST | Ac225-PSMA I&T | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Correct PredictionTP |
| NCT05226507 | NXP800 | ADRI1a-mutated ovarian cancer | Phase 1 | Correct PredictionTN |
| NCT05228015 | IK-930 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05238922 | INCB0123667 | Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05252416VELA | BLU-222 Carboplatin Ribociclib Fulvestrant | Advanced Solid Tumors | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05254743BRUIN-CLL-314 | Pirtobrutinib | Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) | Phase 3 | Correct PredictionTN |
| NCT05256290 | BDTX1535 | advanced EGFRm-NSCLC | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05257408ROSELLA | Relacorilant | platinum-resistant ovarian cancer | Phase 3 | Missed PredictionFN |
| NCT05271604 | Ozuriftamab Vedotin (BA3021) PD-1 inhibitor | Head and Neck Cancer | Phase 2 | Correct PredictionTN |
| NCT05274451 | LYL797 | Solid Tumors | Phase 1 | Correct PredictionTP |
| NCT05275439 | SL-172154 | Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) | Phase 1 | Correct PredictionTN |
| NCT05275478 | TNG908 | MTAP-deleted Solid Tumors | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05275868 | MGY825 | advanced Non-small Cell Lung Cancer | Phase 1 | Correct PredictionTN |
| NCT05304377CML | ELVN-001 | Chronic Myeloid Leukemia | Phase 1 a/1b | Correct PredictionTP |
| NCT05308264 | R906289 Monosodium (R289 Na) | R/R Lower-risk Myelodysplastic Syndromes (LR MDS) that have exhausted all the other treatment options | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05323656 | Setanaxib Pembrolizumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 2 | Correct PredictionTN |
| NCT05326516AUGMENT-102 | SNDX-5613 (Revumenib) Chemotherapy Regimen 1 Chemotherapy Regimen 2 | R/R Acute Leukemia | Phase 1 | Correct PredictionTN |
| NCT05329766EDGE-Gastric | Domvanalimab | Gastrointestinal Tract Malignancies | Phase 2 | Correct PredictionTN |
| NCT05336409ELiPSE-1 | CNTY-101 IL-2 Lymphodepleting Chemotherapy | CD19-Positive B-Cell Malignancies | Phase 1 | Correct PredictionTN |
| NCT05338970HERTHENA-Lung02 | Patritumab Deruxtecan | advanced NSCLC | Phase 3 | Correct PredictionTN |
| NCT05348356 | nirogacestat | Ovarian Granulosa Cell Tumors | Phase 2 | Missed PredictionFP |
| NCT05361668 | Paltusotine | Carcinoid Syndrome | Phase 2 | Correct PredictionTP |
| NCT05370521POWER | Tildacerfont | Polycystic Ovary Syndrome | Phase 2 | Correct PredictionTN |
| NCT05377996 | Emiltatug Ledadotin (XMT-1660) | Triple Negative Breast Cancer Breast Cancer Endometrial Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cavity Cancer Adenoid Cystic Carcinoma | Phase 1 | Correct PredictionTN |
| NCT05379985 | RMC-6236 | RAS Mutant Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05382299ASCENT-03 | Trodelvy (sacituzumab govitecan-hziy) | 1L metastatic Triple-Negative Breast Cancer (TNBC) | Phase 3 | Correct PredictionTN |
| NCT05384626ALKOVE-1 | NVL-655 | Advanced NSCLC and Other Solid Tumors | Phase 1 | Correct PredictionTP |
| NCT05386550XRAY VISION | Xevinapant IMRT Placebo | Head and Neck Cancer | Phase 3 | Correct PredictionTN |
| NCT05389462 | Mipasetamab Uzoptirine (ADCT-601) | advanced solid tumours | Phase 1 | Correct PredictionTN |
| NCT05396885iMMagine-1 | Anitocabtagene-autoleucel | Relapsed or Refractory Multiple Myeloma | Phase 2 | Correct PredictionTN |
| NCT05413421 | ORIC-944 | Metastatic Prostate Cancer | Phase 1 | Correct PredictionTN |
| NCT05425940STELLAR-303 | Zanzalintinib | 2L MSI-high Metastatic Colorectal Cancer | Phase 3 | Correct PredictionTN |
| NCT05433142 | XmAb819 | 2L+ advanced clear cell renal cell carcinoma (ccRCC) | Phase 1 | Correct PredictionTN |
| NCT05450692LATIFY | Ceralasertib | 2L+ NSCLC without actionable genomic alterations (AGAs) | Phase 3 | Correct PredictionTP |
| NCT05462717 | RMC-6291 | Colorectal Cancer (CRC) patients previously treated with KRAS(OFF) G12C inhibitors | Phase 1 | Correct PredictionTN |
| NCT05462873 | QEQ278 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05464030PROCEADE-CRC-01 | M9140 M9140 Bevacizumab Capecitabine | Colorectal Cancer | Phase 1 | Correct PredictionTN |
| NCT05480306DeFianCe | Sirexatamab (DKN-01) | 2L MSS Colorectal Cancer | Phase 2 | Correct PredictionTN |
| NCT05483868 | Belzupacap Sarotalocan (AU-011) | Bladder Cancer | Phase 1 | Correct PredictionTN |
| NCT05497453MYCHELANGELO I | OTX-2002 | advanced solid tumor | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05499390HARMONi-2 | Ivonescimab (AK112) | Advanced Non-small-cell Lung Cancer | Phase 3 | Correct PredictionTP |
| NCT05501054 | Ciforadenant | 1L metastatic renal cell cancer (RCC) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05501886VIKTORIA-1 | Gedatolisib | PIK3CA WT and MT advanced or metastatic HR+/HER2- breast cancer | Phase 3 | Correct PredictionTN |
| NCT05506943COMPANION-002 | Tovecimig (CTX009) | advanced billiard tract cancers | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05508906 | Palazestrant (OP-125) | 2L treatment for HR+/HER2- Metastatic Breast Cancer | Phase 1 | Correct PredictionTP |
| NCT05519449ENGAGER-PSMA-01 | JANX007 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Correct PredictionTN |
| NCT05524545ASPEN-07 | Evorpacept (ALX148) Enfortumab Vedotin | Urothelial Carcinoma | Phase 1 | Correct PredictionTN |
| NCT05536141ARC-20 | casdatifan (AB521) | 3L treatment for metastatic clear cell renal cell carcinoma (ccRCC) | Phase 1 | Correct PredictionTP |
| NCT05544019 | SGR1505 | relapsed/refractory B-cell malignancies | Phase 1 | Correct PredictionTP |
| NCT05544552SURF301 | TYRA-300 | Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05546268 | MRT-2359 | MYC-driven advanced solid tumours | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05546476PROACC-1 | ponsegromab | Cancer Cachexia | Phase 2 | Correct PredictionTN |
| NCT05548296 | ACR-368 Gemcitabine OncoSignature | Ovarian Carcinoma; Endometrial Adenocarcinoma; and Urothelial Carcinoma | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05551117Tamarack | Vobramitamab Duocarmazine | Metastatic Castration Resistant Prostate Cancer | Phase 2 | Correct PredictionTN |
| NCT05552755TUPELO | REC-4881 | Familial Adenomatous Polyposis (FAP) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05552976SUCCESSOR-2 | Mezigdomide | Relapsed or Refractory Multiple Myeloma | Phase 3 | Correct PredictionTP |
| NCT05568095STAR-221 | Domvanalimab | First-Line Upper GI Cancers (Gastric/Esophageal) | Phase 3 | Correct PredictionTN |
| NCT05576077STARLING | TBio-4101 Pembrolizumab | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05599984 | ABBV-706 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT05654623VERITAC-2 | Vepdegestrant | ER+HER2- advanced breast cancer | Phase 3 | Missed PredictionFP |
| NCT05669482RAMP205 | Avutometinib (VS-6766) | 1L Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05712889 | VIP236 | Advanced Cancer | Phase 1 | Missed PredictionFP |
| NCT05718557 | PYX106 | advanced solid tumors | Phase 1 | Correct PredictionTN |
| NCT05720117 | PYX-201 | advanced solid tumor | Phase 1 | Correct PredictionTN |
| NCT05732831 | TNG462 | MTAP-deleted Solid Tumors | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05735184KOMET-007 | Ziftomenib | R/R NPM1-m Acute Myeloid Leukemia | Phase 1 | Correct PredictionTN |
| NCT05743036 | ZN-c3 (azenosertib) | BRAF V600E mutant colorectal cancer | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05756972 | BNT327/PM8002 | Non-Small-Cell Lung | Phase 2 Phase 3 | Correct PredictionTP |
| NCT05775406 | KT-253 | relapsed or refractory (R/R) high grade myeloid malignancies; acute lymphocytic leukemia (ALL); R/R lymphoma; and R/R solid tumors | Phase 1 | Correct PredictionTN |
| NCT05804045MANEUVER | Pimicotinib(ABSK021) | tenosynovial giant cell tumor (TGCT) | Phase 3 | Correct PredictionTP |
| NCT05817058 | AFM28 | Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Correct PredictionTN |
| NCT05878184ARDENT | SC291 | r/r B-cell malignancies | Phase 1 | Correct PredictionTN |
| NCT05883449LuminICE-203 | AFM13 AB-101 Cyclophosphamide Fludarabine Interleukin-2 | Relapsed or Refractory Hodgkin Lymphoma Peripheral T Cell Lymphoma | Phase 2 | Correct PredictionTN |
| NCT05907304SEACRAFT-1 | naporafenib (ERAS254) | RAS-mutant advanced solid tumors | Phase 1 | Correct PredictionTN |
| NCT05907954NADOM | Darovasertib | Localized Ocular Melanoma | Phase 2 | Correct PredictionTP |
| NCT05909397VERITAC-3 | Vepdegestrant | 1L ER+HER2- advanced breast cancer | Phase 3 | Correct PredictionTN |
| NCT05918445 | BNT327/PM8002 | advanced RCC | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05933577INTerpath-001 | intismeran autogene (V940) | High-Risk Stage II-IV Melanoma | Phase 3 | Correct PredictionTP |
| NCT05951179ADVANCED-2 | TARA002 | refractory/relapsed NMIBC | Phase 2 | Correct PredictionTN |
| NCT05961839 | SGR-2921 | Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 1 | Correct PredictionTN |
| NCT05967689REZILIENT2 | Zipalertinib (TAS6417) | ex20in-mt advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Correct PredictionTP |
| NCT05980416 | EO-3021 | Pancreas Neoplasm Stomach Neoplasm Gastrointestinal Neoplasms Digestive System Neoplasm Neoplasms by Site Neoplasms | Phase 1 | Correct PredictionTN |
| NCT05983367 | Ompenaclid | 2L RAS-mutant Metastatic Colorectal Cancer (mCRC) | Phase 2 | Correct PredictionTN |
| NCT05984199 | VCAR33 | Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06040541 | RMC-9805 | KRAS G12D-Mutant Solid Tumors | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06056791CaRe | INKmune | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06106308 | Onvansertib | KRAS/NRAS-mutant 1L mCRC | Phase 2 | Correct PredictionTN |
| NCT06163430CARDINAL | TERN-701 | Relapsed/refractory Chronic Myeloid Leukemia | Phase 1 | Correct PredictionTP |
| NCT06225596Duravelo-2 | zelenectide pevedotin (BT8009) | Metastatic Urothelial Cancer | Phase 2 Phase 3 | Correct PredictionTN |
| NCT06228326KYANITE-1 | KB707 | advanced non-small cell lung cancer (NSCLC) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06251310 | SW-682 | Advanced Solid Tumors | Phase 1 | Correct PredictionTN |
| NCT06265727 | CRB701 | 2L treatment for nectin4-overexpressing advanced solid tumors | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06299761STARMAP | BBI-825 | advanced solid tumours with resistance oncogene amplifications | Phase 1 | Correct PredictionTN |
| NCT06396065HARMONi | Ivonescimab | 2L advanced EGFR-mutant NSCLC | Phase 3 | Correct PredictionTN |
| NCT06449209 | Pumitamig (BNT327) | untreated extended-stage small-cell lung cancer (ES-SCLC) | Phase 2 | Correct PredictionTN |
| NCT06472076GALAXIES Lung-301 | Belrestotug | PDL1 high Non-small-cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
| NCT06555263REFRaME-L1 | Luveltamab Tazevibulin | Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Correct PredictionTN |
| NCT06726265TACTI-004 | Eftilagimod Alfa (Efti) | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Correct PredictionTN |
Nervous System Diseases (117)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03507790SHINE | CT1812 | Mild to Moderate Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT03566043CAMPSIITE | RGX-121 | Mucopolysaccharidosis Type II (Hunter Syndrome) | Phase 2 Phase 3 | Correct PredictionTN |
| NCT04046224STAAR | ST920 | Fabry Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04066244 | BLZ945 | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Correct PredictionTN |
| NCT04120493 | AMT-130 | Early Manifest Huntington's Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04201093TEMPO-1 | tavapadon | early Parkinson's Disease | Phase 3 | Correct PredictionTN |
| NCT04223193TEMPO-2 | Tavapadon | early Parkinson's Disease | Phase 3 | Correct PredictionTN |
| NCT04244175REALIZE | Darigabat (CVL-865) | Focal Onset Seizures | Phase 2 | Correct PredictionTN |
| NCT04259281 | GTX-102 | Angelman Syndrome | Phase 1 Phase 2 | Correct PredictionTP |
| NCT04374136INFRONT-3 | AL001 | Frontotemporal Dementia due to a progranulin gene mutation (FTD-GRN) | Phase 3 | Correct PredictionTN |
| NCT04410978GEMINI 1 | Tolebrutinib | Relapsing Forms of Multiple Sclerosis (RMS) | Phase 3 | Correct PredictionTN |
| NCT04410991GEMINI 2 | Tolebrutinib | Relapsing Forms of Multiple Sclerosis (RMS) | Phase 3 | Correct PredictionTN |
| NCT04411641HERCULES | Tolebrutinib | Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) | Phase 3 | Correct PredictionTN |
| NCT04445831 | ACI-35.030 (JNJ-2056) | Preclinical/Presymptomatic Alzheimer's Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04458051PERSEUS | Tolebrutinib | Primary Progressive Multiple Sclerosis (PPMS) | Phase 3 | Unadjudicatable Prediction |
| NCT04488419LIFT-AD | fosgonimeton (ATH-1017) | Alzheimer's Disease | Phase 2 Phase 3 | Correct PredictionTN |
| NCT04494256ALSpire | BIIB105 | Amyotrophic Lateral Sclerosis and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04498650VIVIAD | PQ912 | Early Alzheimer's Disease Mild Cognitive Impairment Due to AD | Phase 2 | Correct PredictionTN |
| NCT04531982ADVANCE-2 | Pimavanserin | Schizophrenia | Phase 3 | Missed PredictionFP |
| NCT04542499TEMPO-3 | Tavapadon | Parkinson's Disease | Phase 3 | Correct PredictionTN |
| NCT04544449FENtrepid | Fenebrutinib | Primary Progressive Multiple Sclerosis | Phase 3 | Correct PredictionTP |
| NCT04571970 | RGX-121 | paediatric Mucopolysaccharidosis Type II (Hunter Syndrome) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04592874INVOKE-2 | AL002 | Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT04601051 | NTLA-2001 (nex-z) | Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) | Phase 1 | Correct PredictionTN |
| NCT04639050Brainshuttle AD | Trontinemab (RO7126209) | Alzheimer's Disease | Phase 1 Phase 2 | Correct PredictionTP Correct PredictionTN |
| NCT04658186ORCHESTRA | minzasolmin (UCB0599) | Early-stage Parkinson's Disease | Phase 2 | Correct PredictionTN |
| NCT04747431upliFT-D | PBFT02 | Frontotemporal Dementia and Progranulin Mutations (FTD-GRN) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT04777331PADOVA | Prasinezumab | Early Parkinson's Disease | Phase 2 | Correct PredictionTN |
| NCT04777396EVOKE | Semaglutide | Early-Stage Symptomatic Alzheimer's Disease | Phase 3 | Missed PredictionFP |
| NCT04836559 | JNJ-40411813 | Focal Onset Seizures | Phase 2 | Correct PredictionTN |
| NCT04849741 | Zilganersen (ION373) | Alexander Disease (AxD) | Phase 3 | Correct PredictionTN |
| NCT04867616TOGETHER | Bepranemab | Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT04940624SKYLINE | Soticlestat | Dravet Syndrome | Phase 3 | Correct PredictionTN |
| NCT04959032 | Lumateperone | Schizophrenia relapse prevention | Phase 3 | Correct PredictionTP |
| NCT04973657 | VK0214 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | Phase 1 | Correct PredictionTP |
| NCT04977986RECONNECT | ZYN002 | Fragile X Syndrome | Phase 3 | Correct PredictionTN |
| NCT04994483RETHINK-ALZ | Simufilam | Alzheimer's Disease | Phase 3 | Correct PredictionTN |
| NCT05021536Phoenix | AMX0035 | Amyotrophic Lateral Sclerosis | Phase 3 | Missed PredictionFP |
| NCT05026177REFOCUS-ALZ | Simufilam | Mild-to-Moderate Alzheimer's Disease | Phase 3 | Correct PredictionTN |
| NCT05028569 | BOTOX | Episodic Migraine | Phase 3 | Correct PredictionTN |
| NCT05032196SELECT-HD | WVE-003 | Huntington's Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05054140CALLIPER | IMU-838 | Progressive Multiple Sclerosis (PMS) | Phase 2 | Correct PredictionTN |
| NCT05059223SYMPHONY | AXS-12 (reboxetine) | Narcolepsy | Phase 3 | Correct PredictionTP |
| NCT05085561SYCAMORE | REC-994 | Cerebral Cavernous Malformation (CCM) | Phase 2 | Correct PredictionTN |
| NCT05089656STEER | OAV101 (AVXS-101) | Type 2 Spinal Muscular Atrophy (SMA) | Phase 3 | Correct PredictionTN |
| NCT05107128DIMENSION | SAGE-718 (dalzanemdor) | Huntington's Disease | Phase 2 | Correct PredictionTN |
| NCT05122650 | JZP385 | Essential Tremor | Phase 2 | Correct PredictionTN |
| NCT05127226HALOS | ION582 | Angelman Syndrome | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05145413ARISE | Adjunctive KarXT | treatment-resistant schizophrenia | Phase 3 | Missed PredictionFP |
| NCT05156320SAPPHIRE | Apitegromab | Spinal Muscular Atrophy (SMA) | Phase 3 | Correct PredictionTN |
| NCT05173012KINETIC 2 | SAGE-324 | Essential Tremor | Phase 2 | Correct PredictionTN |
| NCT05182476ERUDITE | Luvadaxistat | Schizophrenia | Phase 2 | Correct PredictionTN |
| NCT05206513 | Valbenazine | Dyskinesia Cerebral Palsy | Phase 3 | Missed PredictionFP |
| NCT05206773PERIDOT | Venglustat (GZ402671) | Fabry Disease | Phase 3 | Correct PredictionTN |
| NCT05216250ELATE | BOTOX | Upper Limb Essential Tremor | Phase 2 | Correct PredictionTN |
| NCT05225415COG1201 | CT1812 | Dementia With Lewy Bodies | Phase 2 | Correct PredictionTN |
| NCT05225675ARDA | ARGX-117 | Multifocal Motor Neuropathy | Phase 2 | Correct PredictionTP |
| NCT05227690EMPOWER-1 | Emraclidine (CVL-231) | schizophrenia | Phase 2 | Correct PredictionTN |
| NCT05227703EMPOWER-2 | Emraclidine (CVL-231) | schizophrenia | Phase 2 | Correct PredictionTN |
| NCT05228145CLN5-200 | NGN101 | CLN5 Batten Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05237284HIMALAYA | SAR443820 | Amyotrophic Lateral Sclerosis | Phase 2 | Correct PredictionTN |
| NCT05243017 | AMT-130 | Early Manifest Huntington's Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05280548CARAT | venglustat | Fabry disease | Phase 3 | Correct PredictionTN |
| NCT05318937PRECEDENT | SAGE-718 | Parkinson Disease Cognitive Dysfunction | Phase 2 | Missed PredictionFP |
| NCT05318976MINDFuL | XPro1595 | Early Alzheimer's Disease With Biomarkers of Inflammation | Phase 2 | Correct PredictionTN |
| NCT05323734TrustTSC | Ganaxalone | Tuberous Sclerosis Complex related Epilepsy | Phase 3 | Correct PredictionTN |
| NCT05337553RESILIENT | Taldefgrobep alfa | Spinal Muscular Atrophy (SMA) | Phase 3 | Correct PredictionTN |
| NCT05349721CARDINALS | PTC857 | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Correct PredictionTN |
| NCT05357989 | Buntanetap | Parkinson's Disease | Phase 3 | Correct PredictionTN |
| NCT05358717PIVOT-HD | PTC518 | Huntington's Disease | Phase 2 | Correct PredictionTN |
| NCT05358821SURVEYOR | SAGE-718 | Huntington's Disease | Phase 2 | Correct PredictionTN |
| NCT05364021PACIFIC | LP352 | Developmental and Epileptic Encephalopathies | Phase 1 Phase 2 | Missed PredictionFN |
| NCT05397665INSPIRE | Govorestat (AT007) | Hereditary Neuropathy Caused by SORD Deficiency | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05407324DAZALS | Dazucorilant | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Correct PredictionTN |
| NCT05445323SUNRISE-FA | LX2006 | Friedreich's Ataxia | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05518578RENAISSANCE | SPN-817 | Resistant Epilepsy | Phase 2 | Correct PredictionTN |
| NCT05526066 | ARCT810 | Ornithine Transcarbamylase Deficiency (OTCD) | Phase 2 | Correct PredictionTP |
| NCT05545111 | NBI-1117568 | Schizophrenia | Phase 2 | Correct PredictionTN |
| NCT05550207EMERGE | AXS07 (meloxicam and rizatriptan) | Migraine | Phase 3 | Correct PredictionTP |
| NCT05553366 | VX-548 HB/APAP | Acute Pain After a Bunionectomy | Phase 3 | Correct PredictionTP |
| NCT05557409ADVANCE-2 | AXS-05 | Alzheimer's Disease Agitation | Phase 3 | Missed PredictionFP |
| NCT05558410 | VX-548 | Acute Pain After an Abdominoplasty | Phase 3 | Correct PredictionTN |
| NCT05579691 | CTI-1601 | Friedreich Ataxia | Phase 2 | Correct PredictionTN |
| NCT05614063X-TOLE2 | XEN1101 | Focal Onset Seizures | Phase 3 | Correct PredictionTP |
| NCT05619692LIGHTWAVE | SAGE-718 (dalzanemdor) | Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT05629559INGLAXA | 4D-310 | Fabry Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05633407POTS | Efgartigimod | Postural Orthostatic Tachycardia Syndrome | Phase 2 | Correct PredictionTN |
| NCT05642442 | Suvecaltamide | Moderate to Severe Residual Tremor in Parkinson's Disease | Phase 2 | Correct PredictionTN |
| NCT05668754 | serdexmethylphenidate (SDX) | Idiopathic Hypersomnia | Phase 2 | Correct PredictionTP |
| NCT05677659IGNITE | Iluzanebart (VGL101) | Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia | Phase 2 | Correct PredictionTN |
| NCT05686044 | Buntanetap/Posiphen | Alzheimer Disease | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05686239 | Inidascamine | Cognitive Impairment Associated With Schizophrenia | Phase 2 | Correct PredictionTN |
| NCT05696717CYPRESS | Ampreloxetine | Symptomatic Neurogenic Orthostatic Hypotension MSA - Multiple System Atrophy | Phase 3 | Correct PredictionTN |
| NCT05711940 | COMP360 (psilocybin) | Treatment Resistant Depression | Phase 3 | Correct PredictionTN |
| NCT05722522 | Secukinumab | Rotator Cuff Tendinopathy | Phase 3 | Correct PredictionTN |
| NCT05737784EMBRAVE | Elsunersen | SCN2A-DEE Epilepsy | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05771428Abroad | ABBV-552 | Mild Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT05818553EMBOLD | relutrigine | SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) | Phase 2 | Correct PredictionTP |
| NCT05842941HEALEY | DNL343 | Amyotrophic Lateral Sclerosis | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05869669RewinD-LB | Neflamapimod | Dementia With Lewy Bodies | Phase 2 | Correct PredictionTN |
| NCT05898620EMBOLDEN | NGN-401 | Rett Syndrome | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06015841VacSYn | adjuvant | Parkinson's Disease | Phase 2 | Correct PredictionTN |
| NCT06079190PROGRESS-AD | GSK4527226 (AL101) | Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT06087276Essential3 | Ulixacaltamide | Essential Tremor | Phase 3 | Correct PredictionTN |
| NCT06096090 | aldesleukin | Alzheimer's Disease | Phase 2 | Correct PredictionTN |
| NCT06122662ORION | AMX0035 | Progressive Supranuclear Palsy | Phase 3 | Correct PredictionTN |
| NCT06152237REVEAL | TSHA-102 | Rett Syndrome | Phase 1 | Correct PredictionTN |
| NCT06173531COMPASS PWS | Carbetocin Nasal Spray | Hyperphagia in Prader-Willi Syndrome (PWS) | Phase 3 | Missed PredictionFP |
| NCT06176196 | Suzetrigine (VX-548) | Painful Lumbosacral Radiculopathy | Phase 2 | Correct PredictionTN |
| NCT06358651PALISADE-3 | Fasedienol | Social Anxiety Disorder | Phase 3 | Correct PredictionTN |
| NCT06358950Vibrance-1 | Alixorexton (ALKS 2680) | Narcolepsy Type 1 | Phase 2 | Correct PredictionTP |
| NCT06470828FirstLight | TAK861 | Narcolepsy Type 1 | Phase 3 | Correct PredictionTP |
| NCT06505031RadiantLight | TAK861 | Narcolepsy Type 1 | Phase 3 | Correct PredictionTP |
| NCT06555783Vibrance-2 | Alixorexton (ALKS2680) | Narcolepsy Type 2 | Phase 2 | Correct PredictionTP |
| NCT06556173 | VTX3232 | early Parkinson's Disease (PD) | Phase 2 | Correct PredictionTN |
| NCT06721156MK-1167-008 | MK-1167 | Mild to Moderate Alzheimer's Disease Dementia | Phase 2 | Correct PredictionTN |
| NCT06752668CRYSTAL-1 | ORX750 | Narcolepsy and Idiopathic Hypersomnia | Phase 2 | Correct PredictionTP |
Immune System Diseases (80)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03905525TWINSS | iscalimab (CFZ533) | Sjogren's Syndrome | Phase 2 | Correct PredictionTN |
| NCT04128579EQUALISE | EQ001 (Itolizumab) | Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | Phase 1 | Correct PredictionTP |
| NCT04146051 | Descartes-08 | Generalized Myasthenia Gravis | Phase 2b | Correct PredictionTP |
| NCT04180488LIBERTY-CSU CUPID | dupilumab | chronic spontaneous urticaria (CSU) | Phase 3 | Correct PredictionTN |
| NCT04221477REGENCY | Obinutuzumab | Lupus Nephritis | Phase 3 | Missed PredictionFP |
| NCT04294667PHOENYCS GO | Dapirolizumab Pegol | Systemic Lupus Erythematosus (SLE) | Phase 3 | Correct PredictionTN |
| NCT04524273MINT | Inebilizumab | generalized myasthenia gravis (gMG) | Phase 3 | Correct PredictionTP |
| NCT04540497MITIGATE | Inebilizumab | IgG4 Related Disease | Phase 3 | Missed PredictionFN |
| NCT04566666SOLARES-PsO-1 | SCD-044 | Moderate to Severe Plaque Psoriasis | Phase 2 | Correct PredictionTN |
| NCT04573478ALIGN | atrasentan | IgA Nephropathy | Phase 3 | Correct PredictionTN |
| NCT04701164 | ANX005 | Guillain-Barre Syndrome | Phase 3 | Correct PredictionTN |
| NCT04716231ORIGIN 3 | Atacicept | IgA Nephropathy | Phase 3 | Correct PredictionTN |
| NCT04814368 | LNA043 | Knee Osteoarthritis | Phase 2 | Correct PredictionTN |
| NCT04864392ONWARDS | LNA043 | Knee Osteoarthritis | Phase 2 | Correct PredictionTN |
| NCT04950127GLISTEN | linerixibat | Cholestatic Pruritus (CP) | Phase 3 | Correct PredictionTP |
| NCT04995653 | SER-155 | Graft vs. Host Disease (GvHD) | Phase 1 | Correct PredictionTN |
| NCT05027906 | AT-1501 (Tegoprubart) | prevention of rejection in kidney transplantation | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05064735STEP 9 | Semaglutide | Knee Osteoarthritis | Phase 3 | Correct PredictionTP |
| NCT05083364 | ARO-C3 | IgA nephropathy | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05120830NTLA-2002 | NTLA-2002 | Hereditary Angioedema | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05162586WILLOW | enpatoran (M5049) | systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) | Phase 2 | Correct PredictionTP |
| NCT05198310 | KPL-404 | Rheumatoid Arthritis | Phase 2 | Correct PredictionTN |
| NCT05263999EQUATOR | Itolizumab | Acute Graft Versus Host Disease (aGVHD) | Phase 3 | Correct PredictionTN |
| NCT05350072NEPTUNUS-1 | Ianalumab (VAY736) | Sjögren Syndrome | Phase 3 | Correct PredictionTN |
| NCT05352893GEMINI-1 | Imsidolimab (ANB019) | Generalized Pustular Psoriasis | Phase 3 | Correct PredictionTP |
| NCT05355805 | Izokibep | Hidradenitis Suppurativa | Phase 2 | Correct PredictionTP |
| NCT05403541 | Batoclimab | generalized myasthenia gravis (gMG) | Phase 3 | Correct PredictionTN |
| NCT05415410STARGAZE | Apraglutide | Graft Versus Host Disease (GVHD). | Phase 2 | Correct PredictionTP |
| NCT05499130RELIEVE UCCD | duvakitug (TEV’574/SAR447189) | Severe Ulcerative Colitis and Crohn's Disease | Phase 2 | Correct PredictionTP |
| NCT05516758RESOLUTION-1 | Peresolimab | Rheumatoid Arthritis | Phase 2 | Correct PredictionTN |
| NCT05523167ALKIVIA | Efgartigimod | Active Idiopathic Inflammatory Myopathy | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05525520PACIFIC | INCB000547 (EP547) | Cholestatic Pruritus (CP) | Phase 2 | Correct PredictionTN |
| NCT05556096PREVAIL | Gefurulimab (ALXN1720) | anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG) | Phase 3 | Correct PredictionTN |
| NCT05581199 | Batoclimab | Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Correct PredictionTN |
| NCT05620823STOP-HS1 | Povorcitinib (INCB054707) | Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Correct PredictionTN |
| NCT05620836STOP-HS2 | Povorcitinib (INCB054707) | Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Correct PredictionTN |
| NCT05662241INDIGO | Obexelimab | IgG4 Related Disease | Phase 3 | Missed PredictionFP |
| NCT05688852Harmony-CD | VTX958 | Crohn Disease | Phase 2 | Correct PredictionTN |
| NCT05732402RUBY-3 | Povetacicept (ALPN-303) | immunoglobulin A (IgA) nephropathy; membranous nephropathy; lupus-related kidney disease (lupus nephritis); anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05741476VITESSE | DBV712 | Allergy Peanut | Phase 3 | Correct PredictionTP |
| NCT05767034REPLENISH | Secukinumab | Polymyalgia Rheumatica (PMR) | Phase 3 | Correct PredictionTP |
| NCT05774184EvolvE | Barzolvolimab (CDX-0159) | Eosinophilic Esophagitis (EoE) | Phase 2 | Missed PredictionFP |
| NCT05785715 | ABBV-113 (NX-13) | Moderate to Severe Ulcerative Colitis (UC) | Phase 2 | Correct PredictionTN |
| NCT05810961 | Efgartigimod | Membranous Nephropathy | Phase 2 | Correct PredictionTN |
| NCT05817669rho | Efgartigimod | Primary Sjögren's Syndrome | Phase 2 | Correct PredictionTN |
| NCT05849922HS OBTAIN | Brivekimig (SAR442970) | Hidradenitis Suppurativa | Phase 2 | Correct PredictionTN |
| NCT05856448GALACELA | GLPG3667 | Systemic Lupus Erythematosus | Phase 2 | Missed PredictionFP |
| NCT05905783 | Izokibep | Hidradenitis Suppurativa | Phase 3 | Correct PredictionTP |
| NCT05983770BESTOW | Tegoprubart | Prevention of rejection in kidney transplantation | Phase 2 | Correct PredictionTN |
| NCT06028230ZEN | SAR444656 (KT-474) | Moderate to Severe Hidradenitis Suppurativa | Phase 2 | Correct PredictionTN |
| NCT06041269RENOIR | Rosnilimab | Rheumatoid Arthritis | Phase 2 | Correct PredictionTN |
| NCT06041568 | Imvotamab | Severe Systemic Lupus Erythematosus | Phase 1 | Correct PredictionTN |
| NCT06049017ANTHEM-UC | icotrokinra (JNJ-2113) | Moderately to Severely Active Ulcerative Colitis | Phase 2 | Correct PredictionTN |
| NCT06072157 | AK006 | Chronic Spontaneous Urticaria | Phase 1 | Correct PredictionTN |
| NCT06073093SPECIFI-RA | balinatunfib | rheumatoid arthritis | Phase 2 | Correct PredictionTN |
| NCT06073119SPECIFI-PSO | Balinatunfib | moderate to severe plaque psoriasis | Phase 2 | Correct PredictionTN |
| NCT06077773CALM-CSU | INCB000262 (EP262) | chronic spontaneous urticaria (CSU) | Phase 2 | Correct PredictionTN |
| NCT06087406 | Imvotamab | Moderate to Severe Rheumatoid Arthritis | Phase 1 | Correct PredictionTN |
| NCT06118099 | Amlitelimab | Moderate to Severe Hidradenitis Suppurativa | Phase 2 | Correct PredictionTN |
| NCT06121297RESET-SLE | CABA-201 | Systemic Lupus Erythematosus (SLE) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06127043ROSETTA | Rosnilimab | Moderate to Severe Ulcerative Colitis | Phase 2 | Correct PredictionTN |
| NCT06143878ICONIC-ADVANCE 1 | icotrokinra (JNJ-2113) | Moderate to Severe Plaque Psoriasis | Phase 3 | Correct PredictionTP |
| NCT06162728BEACON | Briquilimab | Chronic Spontaneous Urticaria | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06220604ICONIC-ADVANCE 2 | icotrokinra (JNJ-2113) | Moderate to Severe Plaque Psoriasis | Phase 3 | Correct PredictionTP |
| NCT06333860IMMpactful | Risankizumab | Moderate Plaque Psoriasis | Phase 4 | Correct PredictionTP |
| NCT06343779RAPIDe-3 | Deucrictibant | hereditary angioedema | Phase 3 | Correct PredictionTP |
| NCT06353971SPOTLIGHT | Briquilimab | Chronic Inducible Urticaria | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06411379VELA-2 | Sonelokimab | Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Unadjudicatable Prediction |
| NCT06411899VELA-1 | Sonelokimab | Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Correct PredictionTP |
| NCT06559176 | PM359 | Chronic Granulomatous Disease (CGD) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06586112ONWARD1 | Envudeucitinib (ESK-001) | Plaque Psoriasis | Phase 3 | Correct PredictionTN |
| NCT06588738ONWARD2 | Envudeucitinib (ESK-001) | Plaque Psoriasis | Phase 3 | Correct PredictionTN |
| NCT06597799 | MRT-6160 | autoimmune diseases | Phase 1 | Correct PredictionTP |
| NCT06619990 | XmAb942 | Ulcerative Colitis | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06622070 | SPY072 | rheumatoid arthritis (RA); psoriatic arthritis (PsA); axial spondyloarthritis (axSpA) | Phase 1 | Correct PredictionTP |
| NCT06637631SPECIFI-CD | balinatunfib | Crohn’s disease | Phase 2 | Correct PredictionTN |
| NCT06672718 | SPY002 | Ulcerative Colitis | Phase 1 | Correct PredictionTP |
| NCT06685835CEDAR | Brensocatib | Hidradenitis Suppurativa | Phase 2 | Correct PredictionTN |
| NCT06790121VELVET | Lunsekimig | Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT06867094SPECIFI-UC | balinatunfib | ulcerative colitis | Phase 2 | Correct PredictionTN |
Nutritional and Metabolic Diseases (60)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04153149HELIOS-B | Vutrisiran Sterile Normal Saline (0.9% NaCl) | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Correct PredictionTN |
| NCT04166773SYNERGY-NASH | Tirzepatide (LY3298176) | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Correct PredictionTP |
| NCT04173065VOYAGE | VK2809 | NASH - Nonalcoholic Steatohepatitis | Phase 2 | Correct PredictionTP |
| NCT04365868NAVIGATE | Belapectin | Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 Phase 3 | Correct PredictionTN |
| NCT04424927PROACTIVE | ordesekimab (AMG714/PRV015) | Non-responsive Celiac Disease | Phase 2 | Correct PredictionTN |
| NCT04720534SHASTA-2 | ARO-APOC3 | Severe Hypertriglyceridemia | Phase 2 | Correct PredictionTP |
| NCT04822181ESSENCE | Semaglutide | Non-alcoholic Steatohepatitis | Phase 3 | Correct PredictionTN |
| NCT04963231DAYBREAK | Setmelanotide | Hypothalamic Obesity | Phase 2 | Correct PredictionTP |
| NCT04973137AFFIRM-AL | Birtamimab | AL amyloidosis | Phase 3 | Correct PredictionTN |
| NCT04998201MUIR | ARO-APOC3 | Mixed Dyslipidemia | Phase 2 | Correct PredictionTP |
| NCT05039450SYMMETRY | efruxifermin (EFX) | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Unadjudicatable Prediction |
| NCT05089084PALISADE | ARO-APOC3 | Familial Chylomicronemia | Phase 3 | Correct PredictionTP |
| NCT05093634EMANATE | Setmelanotide | rare, genetically-driven obesities of the MC4R pathway | Phase 3 | Missed PredictionFP |
| NCT05142722BROADWAY | Obicetrapib | Atherosclerotic Cardiovascular Disease (ASCVD) / Heterozygous familial hypercholesterolemia (HeFH) | Phase 3 | Correct PredictionTN |
| NCT05204237 | VK2735 | Weight Loss NASH | Phase 1 | Correct PredictionTP |
| NCT05232071LEGEND | Lanifibranor (IVA337) Placebo Empagliflozin | NASH and Type 2 Diabetes Mellitus | Phase 2 | Correct PredictionTN |
| NCT05275400QWINT-3 | Insulin Efsitora Alfa (LY3209590) Insulin Degludec | Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT05295875MOMENTUM | ALT-801 | Obesity | Phase 2 | Correct PredictionTN |
| NCT05362058QWINT-2 | Insulin Efsitora Alfa (LY3209590) Insulin Degludec | Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT05394519REDEFINE 2 | CagriSema | Overweight Obesity Type 2 Diabetes Mellitus | Phase 3 | Correct PredictionTN |
| NCT05398029Heart-1 | VERVE-101 | heterozygous familial hypercholesterolemia (HeFH) | Phase 1 | Correct PredictionTN |
| NCT05425745BROOKLYN | Obicetrapib | Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 | Correct PredictionTN |
| NCT05462756QWINT-4 | LY3209590 | Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT05511025 | AZD6234 | Obesity | Phase 1 | Correct PredictionTN |
| NCT05567796REDEFINE 1 | CagriSema | Obesity | Phase 3 | Correct PredictionTP |
| NCT05613387 | ZP8396 | Obesity | Phase 1 | Correct PredictionTN |
| NCT05646706STEP UP | Semaglutide | Obesity | Phase 3 | Correct PredictionTP |
| NCT05669599 | MariTide (AMG133) | Obesity Overweight Type 2 Diabetes Mellitus | Phase 2 | Correct PredictionTN |
| NCT05731544COVALENT-111 | BMF-219 | Type 2 Diabetes Mellitus | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05762471 | GSBR-1290 | Overweight or Obesity Type2 Diabetes Mellitus | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05774756TRANSCEND | Setmelanotide | Acquired Hypothalamic Obesity | Phase 3 | Correct PredictionTP |
| NCT05788601DREAM | Dapiglutide | Obesity | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05822830SURMOUNT-5 | tirzepatide | Obesity | Phase 3 | Correct PredictionTP |
| NCT05869903ATTAIN-1 | Orforglipron | Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | Correct PredictionTN |
| NCT05872620ATTAIN-2 | Orforglipron | Obesity or Overweight and Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT05891834 | INV-202 (Monlunabant) | Obesity and Metabolic Syndrome | Phase 2 | Correct PredictionTN |
| NCT05925114 | S-309309 | Obesity | Phase 2 | Correct PredictionTN |
| NCT05971940ACHIEVE-1 | Orforglipron | type 2 diabetes | Phase 3 | Correct PredictionTP |
| NCT05989711IMPACT | Pemvidutide | Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Correct PredictionTN |
| NCT06005597TANDEM | obicetrapib | familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) | Phase 3 | Correct PredictionTP |
| NCT06045221ACHIEVE-3 | Orforglipron | Type 2 Diabetes Inadequately Controlled With Metformin | Phase 3 | Correct PredictionTP |
| NCT06068946VENTURE | VK2735 | Weight Loss | Phase 2 | Correct PredictionTP |
| NCT06109311ACHIEVE-5 | Orforglipron | Type 2 diabetes inadequately controlled with titrated insulin glargine; with or without metformin and/or SGLT-2 inhibitors | Phase 3 | Correct PredictionTP |
| NCT06131437REDEFINE 4 | CagriSema | Obesity | Phase 3 | Correct PredictionTN |
| NCT06132841 | AZD6234 | Obesity | Phase 1 | Correct PredictionTN |
| NCT06152042COVALENT-112 | BMF-219 | Type 1 Diabetes Mellitus | Phase 2 | Correct PredictionTN |
| NCT06153758 | Danuglipron | Obesity | Phase 1 | Correct PredictionTN |
| NCT06164730Heart-2 | VERVE102 | heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) | Phase 1 | Correct PredictionTN |
| NCT06192108ACHIEVE-2 | Orforglipron | Type 2 diabetes inadequately controlled on metformin | Phase 3 | Correct PredictionTP |
| NCT06208215sunRIZE | RZ358 (ersodetug) | Congenital Hyperinsulinism | Phase 3 | Missed PredictionFP |
| NCT06221969REIMAGINE 4 | CagriSema | Type 2 Diabetes | Phase 3 | Correct PredictionTN |
| NCT06282458QUALITY | Enobosarm | Muscle Loss Obesity | Phase 2 | Correct PredictionTN |
| NCT06354660TRANSCEND-T2D-1 | Retatrutide | Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT06445075EMBRAZE | Apitegromab | GLP1RA-related Muscle Preservation for Overweight and Obesity | Phase 2 | Correct PredictionTP |
| NCT06555822 | AZD5004 | Obesity | Phase 1 | Correct PredictionTN |
| NCT06712836VESPER-1 | MET097 | Obesity without type 2 diabetes | Phase 2 | Correct PredictionTP |
| NCT06771115 | VTX3232 | Obesity without type 2 diabetes | Phase 2 | Correct PredictionTN |
| NCT06828055VENTURE | VK2735 | obesity without type 2 diabetes | Phase 2 | Correct PredictionTP |
| NCT06842186INLIGHT | WVE-007 | Obesity and Overweight | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06973720VESPER-3 | MET097 | Obesity Overweight or Obesity | Phase 2 | Correct PredictionTN |
Respiratory Tract Diseases (41)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03626688ADVANCE OUTCOMES | Ralinepag | Pulmonary Arterial Hypertension (PAH) | Phase 3 | Correct PredictionTN |
| NCT04039113COURSE | Tezepelumab | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Correct PredictionTN |
| NCT04133909MATINEE | mepolizumab | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Missed PredictionFN |
| NCT04544293IMPALA-2 | Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Correct PredictionTN |
| NCT04594369ASPEN | Brensocatib | Non-Cystic Fibrosis Bronchiectasis | Phase 3 | Correct PredictionTN |
| NCT04609878KALOS | BREZTRI (PT010) | Inadequately Controlled Severe Asthma | Phase 3 | Correct PredictionTP |
| NCT04609904LOGOS | BREZTRI (PT010) | Inadequately Controlled Severe Asthma | Phase 3 | Correct PredictionTP |
| NCT04701983AERIFY-1 | Itepekimab | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Correct PredictionTN |
| NCT04708782TETON-1 | Inhaled Treprostinil (Tyvaso) | idiopathic pulmonary fibrosis | Phase 3 | Correct PredictionTP |
| NCT04751487AERIFY-2 | Itepekimab | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Correct PredictionTN |
| NCT04851964WAYPOINT | tezepelumab | pancreas Neoplasm Stomach Neoplasm Gastrointestinal Neoplasms Digestive System Neoplasm Neoplasms by Site Neoplasms | Phase 3 | Correct PredictionTP |
| NCT05032066 | Fipaxalparant (HZN825) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Correct PredictionTN |
| NCT05033080SKYLINE 102 | VX-121/TEZ/D-IVA ELX/TEZ/IVA IVA | Cystic Fibrosis | Phase 3 | Correct PredictionTP |
| NCT05036135IMPAHCT | AV-101 | Pulmonary Arterial Hypertension | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05076149SKYLINE 103 | VX-121/TEZ/D-IVA ELX/TEZ/IVA IVA | Cystic Fibrosis | Phase 3 | Correct PredictionTP |
| NCT05147805 | treprostinil palmitil inhalation powder (TPIP) | Pulmonary Arterial Hypertension | Phase 2 | Correct PredictionTP |
| NCT05176951 | Treprostinil Palmitil | Pulmonary Hypertension | Phase 2 | Correct PredictionTP |
| NCT05219968ENLIGHTEN 1 | LYR-210 Sham procedure control Background Therapy | Chronic Rhinosinusitis | Phase 3 | Correct PredictionTN |
| NCT05248230CF | 4D-710 | Cystic Fibrosis | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05255991TETON-2 | Inhaled Treprostinil | Idiopathic Pulmonary Fibrosis | Phase 3 | Correct PredictionTP |
| NCT05274750ANCHOR-1 | Depemokimab (GSK3511294) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | Correct PredictionTP |
| NCT05281523ANCHOR-2 | Depemokimab (GSK3511294) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | Correct PredictionTP |
| NCT05295459ENLIGHTEN 2 | LYR210 | Chronic Rhinosinusitis | Phase 3 | Correct PredictionTN |
| NCT05314517RESOLVE-Lung | Namilumab | Chronic Pulmonary Sarcoidosis | Phase 2 | Correct PredictionTN |
| NCT05321420ELEVATE | LYT100 | Idiopathic Pulmonary Fibrosis | Phase 2 | Correct PredictionTN |
| NCT05327803 | Epetraborole | MAC Lung Disease | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05412004SURMOUNT-OSA | Tirzepatide | Obstructive Sleep Apnea | Phase 3 | Correct PredictionTP |
| NCT05415137EFZO-FIT | Intravenous Efzofitimod | Pulmonary Sarcoidosis | Phase 3 | Correct PredictionTN |
| NCT05421598TIDE-asthma | Amlitelimab | Moderate-to-severe Asthma | Phase 2 | Missed PredictionFP |
| NCT05422222RIDGELINE 105 | VX-121/TEZ/D-IVA | Cystic Fibrosis | Phase 3 | Correct PredictionTP |
| NCT05668741 | VX-522 | cystic fibrosis | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05712538 | ARCT-032 | Cystic Fibrosis | Phase 1 | Correct PredictionTP |
| NCT05934526PROSERA | Seralutinib | Pulmonary Arterial Hypertension | Phase 3 | Correct PredictionTN |
| NCT05935332 | RPT193 | Moderate to Severe T2-high Asthma | Phase 2 | Correct PredictionTN |
| NCT05954988 | LTI-03 | Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Correct PredictionTP |
| NCT05975905TROPOS | Cibotercept (KER-012) | Pulmonary Arterial Hypertension (PAH) | Phase 2 | Correct PredictionTN |
| NCT06013241BiRCh | Brensocatib | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Phase 2 | Correct PredictionTN |
| NCT06102005AIRCULES | Lunsekimig | Asthma | Phase 2 | Correct PredictionTP |
| NCT06196879VALIANT | Verekitug (UPB-101) | Severe Asthma | Phase 2 | Correct PredictionTP |
| NCT06280391 | Itepekimab (SAR440340) | Bronchiectasis | Phase 2 | Correct PredictionTN |
| NCT06592768ETESIAN | briquilimab | Allergic Asthma | Phase 1 | Correct PredictionTN |
Cardiovascular Diseases (31)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03872401VESALIUS-CV | Evolocumab | Patients with cardiovascular risk | Phase 3 | Correct PredictionTP |
| NCT04083339ARISE-HF | AT-001 | Diabetic Cardiomyopathy | Phase 3 | Correct PredictionTN |
| NCT04136171CARDIO-TTRansform | Eplontersen | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Correct PredictionTN |
| NCT04504825CARES | CAEL-101 (anselamimab) | AL amyloidosis | Phase 3 | Correct PredictionTN |
| NCT04512235CARES | CAEL-101 (anselamimab) | AL amyloidosis | Phase 3 | Correct PredictionTN |
| NCT04560998STRIDE | Semaglutide | type 2 diabetes and peripheral artery disease | Phase 3 | Correct PredictionTP |
| NCT04945460CADENCE | Sotatercept | combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF) | Phase 2 | Correct PredictionTN |
| NCT05021835ZEUS | ziltivekimab | Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation | Phase 3 | Correct PredictionTN |
| NCT05030831 | INZ-701 | ABCC6 Deficiency Causing Pseudoxanthoma Elasticum (PXE) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05103332KARDIA-2 | Zilebesiran Olmesartan Amlodipine Indapamide | Hypertension | Phase 2 | Correct PredictionTN |
| NCT05139810OASIS-HAE | Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) | Hereditary Angioedema | Phase 3 | Correct PredictionTP |
| NCT05180240ARCHER | CardiolRx | Acute Myocarditis | Phase 2 | Correct PredictionTN |
| NCT05186818SEQUOIA-HCM | Aficamten (CK-3773274) | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Correct PredictionTP |
| NCT05259917KONFIDENT | KVD900 | Hereditary Angioedema | Phase 3 | Correct PredictionTP |
| NCT05442047 | coramitug (NNC6019-0001) | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Phase 2 | Correct PredictionTN |
| NCT05562934 | XXB750 | Resistant Hypertension | Phase 2 | Correct PredictionTN |
| NCT05565742ALPACA | muvalaplin | atherosclerotic cardiovascular disease | Phase 2 | Correct PredictionTP |
| NCT05582395ODYSSEY-HCM | Mavacamten | non-obstructive hypertrophic cardiomyopathy (nHCM) | Phase 3 | Correct PredictionTN |
| NCT05618808ROXI-VTE-I | REGN9933 | Venous thromboembolism (VTE) | Phase 2 | Correct PredictionTN |
| NCT05636176HERMES | ziltivekimab | Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation | Phase 3 | Correct PredictionTN |
| NCT05695248ALPHA-STAR | STAR-0215 | Hereditary Angioedema | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05767346MAPLE-HCM | Aficamten | Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Correct PredictionTP |
| NCT05769608Advance-HTN | Lorundrostat | uncontrolled hypertension | Phase 2 | Correct PredictionTN |
| NCT06034743BaxHTN | Baxdrostat | Uncontrolled or resistant hypertension | Phase 3 | Correct PredictionTP |
| NCT06081894ACACIA-HCM | Aficamten | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (non-obstructive HCM) | Phase 3 | Correct PredictionTP |
| NCT06150924Explore-CKD | Lorundrostat | hypertension and Chronic Kidney Disease (CKD) with albuminuria | Phase 2 | Correct PredictionTP |
| NCT06153693Launch-HTN | Lorundrostat | Uncontrolled and Resistant Hypertension | Phase 3 | Correct PredictionTP |
| NCT06200207ATHENA | ziltivekimab | Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation | Phase 3 | Correct PredictionTN |
| NCT06272487KARDIA-3 | Zilebesiran | Uncontrolled hypertension | Phase 2 | Correct PredictionTN |
| NCT06347159CIRRUS-HCM | EDG-7500 | Hypertrophic Cardiomyopathy (HCM) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06785454EXPLORE-OSA | Lorundrostat | Obstructive Sleep Apnea Hypertension | Phase 2 | Correct PredictionTN |
Skin and Connective Tissue Diseases (31)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04598451ADDRESS | Efgartigimod | Pemphigus | Phase 3 | Correct PredictionTN |
| NCT04684485SOLARES-AD-1 | SCD-044 | Moderate to Severe Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT04821089LANTIC | IPN10200 (corabotase) | Moderate to Severe Upper Facial Lines | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05155085ATLAS | Lirentelimab (AK002) | Atopic Dermatitis | Phase 2 | Missed PredictionFP |
| NCT05368103 | daxdilimab | Alopecia Areata | Phase 2 | Correct PredictionTN |
| NCT05372419ADmirable | Lebrikizumab (LY3650150) | Atopic Dermatitis and Skin of Color | Phase 3 | Correct PredictionTP |
| NCT05398445ROCKET-Ignite | Rocatinlimab | Moderate-to-sever Atopic Dermatitis | Phase 3 | Correct PredictionTN |
| NCT05399368 | RPT193 | Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT05405660 | Barzolvolimab Matching Placebo | Chronic Inducible Urticaria | Phase 2 | Correct PredictionTP |
| NCT05432596 | ATI-1777 | Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT05437263VALOR | Brepocitinib | Dermatomyositis | Phase 3 | Correct PredictionTP |
| NCT05496465 | ARS-1 | Urticaria | Phase 2 | Correct PredictionTN |
| NCT05509023SIGNAL-AD | Bempikibart (ADX-914) | Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT05589610 | EQ101 | Moderate to Severe Alopecia Areata | Phase 2 | Correct PredictionTP |
| NCT05651711ROCKET-Horizon | Rocatinlimab | Atopic Dermatitis | Phase 3 | Correct PredictionTP |
| NCT05695950GALARISSO | GLPG3667 | Dermatomyositis | Phase 2 | Correct PredictionTN |
| NCT05724199ROCKET-SHUTTLE | Rocatinlimab | Moderate-to-sever Atopic Dermatitis | Phase 3 | Correct PredictionTN |
| NCT05935085ARISE-AD | ANB032 | Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT06012240Up-AA | Upadacitinib | Alopecia Areata | Phase 3 | Correct PredictionTP |
| NCT06018428SIGNAL-AA | Bempikibart (ADX-914) | Severe Alopecia Areata | Phase 2 | Correct PredictionTN |
| NCT06058156ADVANTA | SAR444656 (KT-474) | Moderate to Severe Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT06118411Viti-Up | Upadacitinib | Vitiligo | Phase 3 | Correct PredictionTP |
| NCT06136741REZOLVE-AD | Rezpegaldesleukin (Rezpeg) | Moderate to Severe Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT06340360REZOLVE-AA | Rezpegaldesleukin | severe-to-very-severe alopecia areata | Phase 2 | Correct PredictionTN |
| NCT06345404 | Soquelitinib | atopic dermatitis | Phase 1 | Correct PredictionTP |
| NCT06395948APEX | APG777 | moderate-to-severe Atopic Dermatitis | Phase 2 | Correct PredictionTN |
| NCT06493578 | VYN201 (repibresib) | Non-segmental Vitiligo | Phase 2 | Correct PredictionTN |
| NCT06585202 | ATI-2138 | Moderate to Severe Atopic Dermatitis | Phase 2 | Correct PredictionTP |
| NCT06673667 | KT621 | moderate-to-severe atopic dermatitis | Phase 1 | Correct PredictionTN |
| NCT06724614 | VDPHL01 (extended-release oral minoxidil) | Male Androgenetic Alopecia | Phase 2 Phase 3 | Correct PredictionTP |
| NCT06724900Pearl-2 | KB304 | Moderate to Severe Wrinkles of the Décolleté | Phase 1 Phase 2 | Correct PredictionTN |
Mental Disorders (25)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04641143 | Troriluzule | Obsessive Compulsive Disorder | Phase 3 | Correct PredictionTN |
| NCT04693351 | Troriluzule | Obsessive Compulsive Disorder | Phase 3 | Correct PredictionTN |
| NCT04855747RELIANCE-II | REL-1017 | Major Depressive Disorder Depression (MDD) | Phase 3 | Correct PredictionTN |
| NCT04985942 | Lumateperone | Major Depressive Disorder | Phase 3 | Correct PredictionTP |
| NCT05061706 | Lumateperone | Major Depressive Disorder | Phase 3 | Correct PredictionTP |
| NCT05066672 | SPN820 (NV-5138) | treatment-resistant depression | Phase 2 | Correct PredictionTN |
| NCT05203341SAVITRI | NBI-1065845 | Major Depressive Disorder | Phase 2 | Correct PredictionTN |
| NCT05455684VENTURA-1 | Aticaprant | Major Depressive Disorder (MDD) | Phase 3 | Correct PredictionTN |
| NCT05550532VENTURA-2 | Aticaprant | Major Depressive Disorder (MDD) | Phase 3 | Correct PredictionTN |
| NCT05624268 | COMP360 | treatment-resistant depression (TRD) | Phase 3 | Correct PredictionTN |
| NCT05712187 | ALTO-100 | Major Depressive Disorder | Phase 2 | Correct PredictionTN |
| NCT05800860 | GH001 | treatment-resistant depression | Phase 2 | Correct PredictionTP |
| NCT05804708 | GH001 | Postpartum Depression | Phase 2 | Correct PredictionTP |
| NCT05839509 | GH001 | Bipolar II Disorder | Phase 2 | Correct PredictionTP |
| NCT05870540 | BPL-003 | Treatment Resistant Depression | Phase 2 | Correct PredictionTP |
| NCT05922878 | ALTO-300 | Major Depressive Disorder | Phase 2 | Correct PredictionTN |
| NCT05941442 | Darigabat (CVL-865) | Panic Disorder | Phase 2 | Correct PredictionTN |
| NCT05972044FOCUS | Solriamfetol | attention deficit hyperactivity disorder (ADHD) | Phase 3 | Unadjudicatable Prediction |
| NCT06011577RELIGHT | REL-1017 | major depressive disorder (MDD) | Phase 3 | Correct PredictionTN |
| NCT06029426KOASTAL-1 | Navacaprant (NMRA-335140) | Major Depressive Disorder | Phase 3 | Correct PredictionTN |
| NCT06051721 | HLP004(CYB004) | Generalized Anxiety Disorder | Phase 2 | Correct PredictionTP |
| NCT06267846 | NBI-1070770 | Major Depressive Disorder | Phase 2 | Correct PredictionTN |
| NCT06360419PARADIGM | Solriamfetol | major depressive disorder (MDD) | Phase 3 | Unadjudicatable Prediction |
| NCT06419608 | BHV-7000 | Major Depressive Disorder | Phase 2 | Correct PredictionTN |
| NCT06987513RECLAIM | Pemvidutide | Alcohol Use Disorder (AUD) | Phase 2 | Correct PredictionTP |
Musculoskeletal Diseases (23)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04004065MOMENTUM | SRP-5051 | Duchenne Muscular Dystrophy (DMD) | Phase 2 | Correct PredictionTN |
| NCT04281485CIFFREO | PF-06939926 | Duchenne Muscular Dystrophy (DMD) | Phase 3 | Correct PredictionTN |
| NCT04886258 | DFV890 | Symptomatic Knee Osteoarthritis | Phase 2 | Correct PredictionTN |
| NCT04906460FORWARD-53 | WVE-N531 | Duchenne Muscular Dystrophy (DMD) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05027269MARINA | AOC 1001 | Myotonic Dystrophy Type 1 (DM1) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05125809Orbit | Setrusumab (UX143) | Osteogenesis Imperfecta | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05192382PATHFNDR-2 | Paltusotine | Acromegaly | Phase 3 | Correct PredictionTP |
| NCT05291091CANYON | Sevasemten (EDG-5506) | Becker Muscular Dystrophy | Phase 2 | Correct PredictionTN |
| NCT05397470REACH | Losmapimod | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 | Correct PredictionTN |
| NCT05481879ACHIEVE | DYNE-101 | Myotonic Dystrophy Type 1 | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05524883DELIVER | DYNE-251 | Duchenne Muscular Dystrophy (DMD) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05598320ApproaCH | TransCon CNP | Achondroplasia | Phase 2 Phase 3 | Correct PredictionTP |
| NCT05623345 | Izokibep | Psoriatic Arthritis | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05670730EXPLORE44 | AOC1044 (del-zota) | Duchenne Muscular Dystrophy (DMD) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05747924FORTITUDE | AOC 1020 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05768854Cosmic | Setrusumab (UX143) | paediatric Osteogenesis Imperfecta | Phase 3 | Correct PredictionTN |
| NCT05775848Fortify | BBP-418 (Ribitol) | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | Correct PredictionTN |
| NCT06079736CONNECT1-EDO51 | PGN-EDO51 | Duchenne Muscular Dystrophy (DMD) | Phase 2 | Correct PredictionTP |
| NCT06204809FREEDOM-DM1 | PGN-EDODM1 | Myotonic Dystrophy Type 1 | Phase 1 | Correct PredictionTN |
| NCT06411288HARBOR | del-desiran (AOC 1001) | myotonic dystrophy type 1 | Phase 3 | Correct PredictionTN |
| NCT06433557COACH | Navepegritide | children with achondroplasia (ACH) | Phase 2 | Correct PredictionTP |
| NCT06524687 | Imvotamab | Idiopathic Inflammatory Myopathies | Phase 1 | Correct PredictionTN |
| NCT06667453FREEDOM2-DM1 | PGN-EDODM1 | Myotonic Dystrophy 1 | Phase 2 | Correct PredictionTP |
Eye Diseases (21)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04514653AAVIATE | RGX-314 Ranibizumab Local steroid Topical steroid | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Correct PredictionTN |
| NCT04671433LUMEOS | botaretigene sparoparvovec (bota-vec) | X-linked retinitis pigmentosa (XLRP) | Phase 3 | Correct PredictionTN |
| NCT04757610ShORe | OPT-302 | Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Correct PredictionTN |
| NCT04757636COAST | OPT-302 | Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Correct PredictionTN |
| NCT05176639THRIVE | VRDN 001 | Thyroid Eye Disease (TED) | Phase 3 | Correct PredictionTP |
| NCT05197270PRISM | 4D-150 IVT Aflibercept IVT | Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05201170MELODY-1 | PL9643 Vehicle Opthalmic Solution Opthalmic Solution | Dry Eye | Phase 3 | Correct PredictionTN |
| NCT05335122 | OTX-TIC (Travoprost) | Open Angle Glaucoma Ocular Hypertension | Phase 2 | Correct PredictionTP |
| NCT05383209PAVIA | EYP-1901 Sham IVT | Nonproliferative Diabetic Retinopathy | Phase 2 | Missed PredictionFP |
| NCT05384249 | izokibep | uveitis | Phase 2 | Correct PredictionTN |
| NCT05517421GO | Batoclimab | Thyroid Eye Disease | Phase 3 | Correct PredictionTN |
| NCT05524571GO | Batoclimab | Thyroid Eye Disease | Phase 3 | Correct PredictionTN |
| NCT05536973LUNA | ADVM-022 | Neovascular Age-related Macular Degeneration | Phase 2 | Correct PredictionTN |
| NCT05683496TED | lonigutamab | Thyroid Eye Disease (TED) | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05727878CHASE | KPI-012 | Persistent corneal epithelial defect (PCED) | Phase 2 | Correct PredictionTN |
| NCT05891548ODYSSEY | CLS-AX | Wet Age-Related Macular Degeneration | Phase 2 | Correct PredictionTN |
| NCT05893537MAGNIFY | CT1812 | geographic atrophy (GA) secondary to dry age-related macular degeneration | Phase 2 | Correct PredictionTN |
| NCT06021054THRIVE-2 | veligrotug (VRDN-001) | Chronic Thyroid Eye Disease | Phase 3 | Correct PredictionTP |
| NCT06099184VERONA | EYP-1901 | Diabetic Macular Edema | Phase 2 | Correct PredictionTP |
| NCT06223958SOL-1 | OTX-TKI | Neovascular Age-Related Macular Degeneration | Phase 3 | Correct PredictionTN |
| NCT06424444 | Reproxalap Ophthalmic Solution (0.25%) Vehicle ophthalmic solution | Dry Eye Disease | Phase 3 | Correct PredictionTP |
Infections (20)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04010539EAGLE-1 | Gepotidacin Ceftriaxone Azithromycin | Urinary Tract Infections | Phase 3 | Correct PredictionTP |
| NCT04684914 | HepTcell | Chronic Hepatitis B | Phase 2 | Correct PredictionTN |
| NCT04816721RSVPEDs | zelicapavir (EDP-938) | respiratory syncytial virus (RSV) | Phase 2 | Correct PredictionTP |
| NCT04856085MARCH | VIR-2218 (elebsiran) VIR-3434 (tobevibart) | Chronic hepatitis B viral infection | Phase 2 | Correct PredictionTP Correct PredictionTN |
| NCT05085366CMVictory | mRNA-1647 | Cytomegalovirus Infection | Phase 3 | Correct PredictionTN |
| NCT05115942 | Hydronidone (F351) | Chronic Viral Hepatitis B | Phase 3 | Correct PredictionTP |
| NCT05281094NEST-IN1 | HIL-214 | Norovirus | Phase 2 Phase 3 | Missed PredictionFP |
| NCT05387083CARPO | TP-05 | Lyme Disease | Phase 2 | Correct PredictionTP |
| NCT05461170SOLSTICE | VIR-2218 (elebsiran) VIR-3434 (tobevibart) | Chronic Hepatitis D Infection | Phase 2 | Correct PredictionTN |
| NCT05477524VALOR | PF-07307405 (LB6V) | Lyme Disease | Phase 3 | Correct PredictionTP |
| NCT05540522 | Quadrivalent modRNA vaccine | Influenza | Phase 3 | Correct PredictionTN |
| NCT05566639 | mRNA-1010 | influenza | Phase 3 | Correct PredictionTN |
| NCT05568706RSVHR | EDP-938 (zelicapavir) | Respiratory Syncytial Virus (RSV) | Phase 2 | Correct PredictionTN |
| NCT05823974 | Flu mRNA | Influenza | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05844423 | VAX24 | invasive pneumococcal disease prevention | Phase 2 | Correct PredictionTP |
| NCT05904470 | Bemnifosbuvir Ruzasvir | Chronic Hepatitis C Virus | Phase 2 | Correct PredictionTP |
| NCT06151288 | VAX-31 | invasive pneumococcal disease (IPD) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06170242 | EDP-323 | RSV Infection | Phase 2 | Correct PredictionTP |
| NCT06569823 | Z-1018 | Shingles | Phase 1 Phase 2 | Correct PredictionTN |
| NCT06907290AZURE-1 | Brelovitug (BJT-778) | Chronic Hepatitis Delta Virus (HDV) Infection | Phase 2 Phase 3 | Correct PredictionTN |
Hemic and Lymphatic Diseases (12)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04455841 | INCB000928 | Anemia Due to Myeloproliferative Disorders | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04624659HIBISCUS | Etavopivat | Sickle Cell Disease | Phase 3 | Correct PredictionTN |
| NCT04717414INDEPENDENCE | Luspatercept | Myelofibrosis-Associated Anemia | Phase 3 | Missed PredictionFP |
| NCT04770779ENERGIZE-T | Mitapivat | Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Phase 3 | Correct PredictionTN |
| NCT04853576RUBY | EDIT-301 | severe sickle cell disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT04927247THRIVE-132 | Inclacumab | Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Phase 3 | Correct PredictionTN |
| NCT05031780RISE UP | Mitapivat (AG-348) | Sickle Cell Disease | Phase 2 Phase 3 | Correct PredictionTN |
| NCT05169580PIONEER | Pociredir | sickle cell disease | Phase 1 | Correct PredictionTN |
| NCT05320198RALLY-MF | DISC-0974 | Anemia | Phase 1 Phase 2 | Correct PredictionTP |
| NCT05444894EdiTHAL | EDIT-301 | Transfusion-Dependent Beta Thalassemia | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05456880BEACON | BEAM-101 | Sickle Cell Disease | Phase 1 Phase 2 | Correct PredictionTN |
| NCT05786573SApHiAre | Obexelimab | Warm Autoimmune Hemolytic Anemia | Phase 3 | Correct PredictionTN |
Cardiovascular Diseases and Nutritional and Metabolic Diseases (10)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03574597SELECT | Semaglutide | Cardiovascular risk in obesity patients | Phase 3 | Correct PredictionTP |
| NCT03914326SOUL | Semaglutide | Cardiovascular Outcomes with Type 2 Diabetes | Phase 3 | Correct PredictionTP |
| NCT04204252InnovAATe | inhaled AAT | Alpha 1-Antitrypsin Deficiency (AATD) | Phase 3 | Correct PredictionTN |
| NCT04255433SURPASS-CVOT | Tirzepatide | Type 2 Diabetes Mellitus (T2DM) and heart disease | Phase 3 | Correct PredictionTP |
| NCT04847557SUMMIT | Tirzepatide (LY3298176) | Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity | Phase 3 | Correct PredictionTP |
| NCT04916470STEP HFpEF DM | Semaglutide | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus Type 2 | Phase 3 | Correct PredictionTN |
| NCT05552326CORE2 | Olezarsen | Severe Hypertriglyceridemia | Phase 3 | Correct PredictionTP |
| NCT06049082Serpentine-1 | Nebulization (KB408) | Alpha 1-Antitrypsin Deficiency (AATD) | Phase 1 | Correct PredictionTP |
| NCT06405633RestorAATion-2 | WVE-006 | alpha-1 antitrypsin deficiency (AATD) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06677307REWRITE | KRRO-110 | Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1 Phase 2 | Correct PredictionTN |
Urogenital Diseases (8)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04457336CAHmelia-203 | Tildacerfont | Congenital Adrenal Hyperplasia | Phase 2 | Correct PredictionTN |
| NCT04544410CAHmelia-204 | Tildacerfont | Adult Congenital Adrenal Hyperplasia (CAH) | Phase 2 | Correct PredictionTN |
| NCT05067127VALIANT | Pegcetacoplan | C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) | Phase 3 | Correct PredictionTP |
| NCT05128942CAHptain-205 | Tildacerfont | pediatric Congenital Adrenal Hyperplasia (CAH) | Phase 2 | Correct PredictionTN |
| NCT05514548 | Monlunabant (INV202) | Diabetic Kidney Disease | Phase 2 | Correct PredictionTN |
| NCT05690386New InsiGHTS | Lonapegsomatropin | Turner Syndrome | Phase 2 | Correct PredictionTP |
| NCT05907291TouCAHn | CRN04894 | Congenital Adrenal Hyperplasia (CAH) | Phase 2 | Correct PredictionTP |
| NCT06362759TRANQUILITY | Pacibekitug (TOUR006) | Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein (Hs-CRP) | Phase 2 | Correct PredictionTP |
Endocrine System Diseases (6)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03697109GRACE | Relacorilant | Cushing Syndrome | Phase 3 | Correct PredictionTN |
| NCT04308590GRADIENT | Relacorilant | Hypercortisolism | Phase 3 | Correct PredictionTN |
| NCT05680818CALIBRATE | Encaleret | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 3 | Correct PredictionTN |
| NCT05778071CALYPSO | Eneboparatide (AZP-3601) | Chronic Hypoparathyroidism (HypoPT) | Phase 3 | Correct PredictionTP |
| NCT05804669 | CRN04894 | ACTH-Dependent Cushing’s Syndrome (ADCS) | Phase 1 Phase 2 | Correct PredictionTP |
| NCT06465108Avail | MBX2109 (Canvuparatide) | Hypoparathyroidism | Phase 2 | Correct PredictionTN |
Digestive System Diseases (4)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04627025STARS | Apraglutide | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | Phase 3 | Correct PredictionTP |
| NCT05071716RED-C-3131 | Rifaximin SSD | Hepatic Encephalopathy | Phase 3 | Correct PredictionTN |
| NCT05297448RED-C-3132 | Rifaximin SSD | Hepatic Encephalopathy | Phase 3 | Correct PredictionTN |
| NCT05900050UNVEIL-IT | VS-01 | Acute-on-Chronic Liver Failure and Ascites | Phase 2 | Correct PredictionTN |
Hematologic Diseases (4)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT04370054AFFINE | PF-07055480 / Giroctocogene Fitelparvovec | Hemophilia A | Phase 3 | Correct PredictionTP |
| NCT04770753ENERGIZE | Mitapivat | Non-Transfusion-Dependent Alpha- or Beta-Thalassemia | Phase 3 | Correct PredictionTN |
| NCT05053139FRONTIER 2 | NNC0365-3769 (Mim8) | Haemophilia A | Phase 3 | Correct PredictionTP |
| NCT05611801BASIS KIDS | Marstacimab | Hemophilia A Hemophilia B | Phase 3 | Correct PredictionTP |
Congenital; Hereditary; and Neonatal Diseases and Abnormalities (1)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT05139316GlucoGene | DTX401 Placebo Oral corticosteroids Placebo for oral corticosteroids | Glycogen Storage Disease Type IA (GSDIa) | Phase 3 | Correct PredictionTP |
Nervous System Diseases / Genetic Diseases (1)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT05676034HELIOS | AMX0035 | Wolfram Syndrome | Phase 2 | Correct PredictionTP |
Nutritional and Metabolic Diseases and Urogenital Diseases (1)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT05018416REGEN-007 | Renal Autologous Cell Therapy | Type 1 or 2 Diabetes and Chronic Kidney Disease | Phase 2 | Correct PredictionTN |
Nutritional and Metabolic Diseases, Immune System Diseases (1)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT05931367TRIUMPH-4 | retatrutide | obesity with knee osteoarthritis | Phase 3 | Correct PredictionTP |
Renal Replacement Therapy (1)
| NCTID | Drug Name | Indication | Phase | Prediction Accuracy |
|---|---|---|---|---|
| NCT03183245 | Biological- Human Acellular Vessel (HAV) Procedure- Arteriovenous fistula (AVF) | Hemodialysis | Phase 3 | Correct PredictionTP |